Meloxicam for Postoperative Pain in Mohs Micrographic Surgery
University of Oklahoma
Summary
The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are: * To provide more information to the Mohs surgery community regarding postoperative pain control. * Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience. * To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen). Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction. Participants will be asked to complete pain and patient satisfaction surveys.
Description
Mohs micrographic surgery (MMS) is a microscope-guided tissue-sparing surgical procedure for the removal of certain skin cancers, in which 100% of the surgical margin is examined. It is the gold-standard for the treatment of high-risk and aggressive nonmelanoma skin cancer. It is an incredibly safe procedure and postoperative complications are uncommon, occurring in only 0.72% of cases. It is the most cost-effective form of skin cancer removal and has higher cure rates when compared to standard excision. Despite the safety and tolerability of the procedure, postoperative patient concerns have…
Eligibility
- Age range
- 18–110 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * All adult patients who consents to the study and are undergoing Mohs micrographic surgery at the University of Oklahoma. Exclusion Criteria: * Women who are pregnant, suspected to be pregnant, or planning to become pregnant during the study period will be excluded from participation. * Chronic liver disease (chronic hepatitis, acute hepatitis, cirrhosis, NASH, NAFLD, alcoholic liver disease, hemochromatosis, Wilson's disease) * Chronic kidney disease stage III or greater, * Aspirin-sensitive asthma * History of chronic NSAID use * Patients vulnerable to drug interactio…
Interventions
- DrugMeloxicam 7.5 mg
This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.
- DrugMeloxicam 15 mg
This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.
- DrugAcetaminophen 500mg
This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.
Location
- University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma